Equities Analysts Offer Predictions for CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Caribou Biosciences in a report released on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings per share of ($2.17) for the year. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Separately, HC Wainwright reissued a "buy" rating and set a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Caribou Biosciences Stock Down 0.8%

CRBU traded down $0.01 during midday trading on Wednesday, hitting $1.17. 603,662 shares of the company traded hands, compared to its average volume of 1,371,493. The company's 50-day moving average is $0.92 and its 200 day moving average is $1.28. The firm has a market capitalization of $108.82 million, a PE ratio of -0.71 and a beta of 2.44. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.00.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.35 million for the quarter, compared to analysts' expectations of $1.48 million.

Institutional Trading of Caribou Biosciences

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of Caribou Biosciences by 475.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after purchasing an additional 2,062,563 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in Caribou Biosciences during the fourth quarter valued at approximately $1,921,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Caribou Biosciences during the first quarter valued at approximately $559,000. Schonfeld Strategic Advisors LLC increased its holdings in Caribou Biosciences by 28.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after buying an additional 467,738 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company's stock worth $480,000 after acquiring an additional 463,391 shares during the period. Hedge funds and other institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.